A recent Brazilian study suggests that fish oil may play a key role in reducing insulin resistance and improving glucose tolerance, offering hope for non-obese individuals with type 2 diabetes.

A groundbreaking Brazilian study has revealed that fish oil supplementation could potentially reverse insulin resistance, particularly in non-obese individuals. The study, published in Nutrients, sheds new light on the relationship between omega-3 fatty acids and insulin resistance, offering hope for the 10%–20% of the global population with non-obese type 2 diabetes.

This preclinical research, funded by FAPESP, was conducted on Goto-Kakizaki (GK) rats, a model for non-obese type 2 diabetes. For eight weeks, rats were administered 2 grams of fish oil per kilogram of body weight, containing 540 mg/g of eicosapentaenoic acid (EPA) and 100 mg/g of docosahexaenoic acid (DHA). The results showed a remarkable reduction in insulin resistance, accompanied by improved blood sugar levels, lipid profiles, and inflammatory markers.

Omega-3 fatty acids have long been recognized for their cardiovascular benefits, but their impact on insulin resistance in non-obese individuals was poorly understood. This study is the first to demonstrate that fish oil supplementation can modulate immune cells—particularly lymphocytes—by shifting them from a pro-inflammatory to an anti-inflammatory state, thereby reversing insulin resistance.

Rui Curi, director of the Butantan Institute and coordinator of the study, explained that the findings suggest a potential link between inflammation and insulin resistance, even in the absence of obesity. The altered immune response seen in the GK rats parallels what is observed in obese individuals with insulin resistance, where immune cells like lymphocytes and macrophages produce pro-inflammatory cytokines.

The study further highlights the critical role of systemic inflammation in the development of insulin resistance. While obesity is a well-known risk factor, systemic inflammation in non-obese individuals may also contribute to the onset of type 2 diabetes. Curi suggests that the primary cause of insulin resistance in non-obese individuals could be genetic, and further research is necessary to explore the full range of factors contributing to the condition.

The study’s findings open new possibilities for treating non-obese type 2 diabetes patients, offering a potential therapeutic route that avoids the need for weight loss. This exciting research paves the way for further investigations into the impact of omega-3 fatty acids on diabetes and related metabolic conditions.

The researchers plan to continue studying the mechanisms behind insulin resistance in non-obese animals, expanding their understanding of how systemic inflammation influences diabetes. If future studies confirm the potential of fish oil in managing insulin resistance, it could revolutionize the way we treat diabetes and other inflammatory diseases.

Copied